Sqz Biotechnologies Co (SQZ) Stock
SQZ is no longer traded. Sqz Biotechnologies Co was delisted from the NYSE in September 2023.
Prices on this page are historical; the last trade was September 1, 2023 at $0.05.
Sqz Biotechnologies Co stock price history
SQZ final trading statistics
- Final close
- $0.05
- Final trading day
- Sep 1, 2023
- Market cap at delisting
- $12.83M
- Shares outstanding
- 29.49M
- Final 52-week range
- $0.01 – $3.39
- Avg. volume (final 3 mo.)
- 704,122
- All-time high (split-adj.)
- $345.80 · Dec 2020
- All-time low (split-adj.)
- $0.05 · Aug 2023
- Return since IPO
- -100.0%
- Beta
- 2.71
- Book value / share
- $1.36
- Price / book
- 0.04
Sqz Biotechnologies Co annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $21.03M | -$78.2M | -$2.76 |
| FY2021 | $27.10M | -$68.7M | -$2.50 |
| FY2020 | $21.00M | -$50.0M | -$8.96 |
| FY2019 | $19.32M | -$32.2M | — |
| FY2018 | $12.67M | -$19.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Sqz Biotechnologies Co
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Sqz Biotechnologies Co stock FAQ
What happened to Sqz Biotechnologies Co stock?
Sqz Biotechnologies Co stock was delisted from the NYSE. Its final close was $0.05 on September 1, 2023.
Is SQZ stock still trading?
No. SQZ was delisted from the NYSE in September 2023 and no longer trades on a U.S. exchange.
What was the last price of SQZ stock?
SQZ closed at $0.05 on its final trading day, September 1, 2023, for a market value of about $12.83M.
What were Sqz Biotechnologies Co's revenue and earnings in its last full fiscal year?
Sqz Biotechnologies Co reported revenue of $21.03M and net income of -$78.2M in fiscal 2022, its last full year as a public company.
When did Sqz Biotechnologies Co go public?
Sqz Biotechnologies Co stock began trading on October 30, 2020.